These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 22707353

  • 1. Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State.
    Hannan EL, Zhong Y, Wu C, Walford G, Holmes DR, Jacobs AK, Stamato NJ, Venditti FJ, Sharma S, Fergus I, King SB.
    Catheter Cardiovasc Interv; 2013 Jun 01; 81(7):1097-105. PubMed ID: 22707353
    [Abstract] [Full Text] [Related]

  • 2. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS.
    JACC Cardiovasc Interv; 2014 May 01; 7(5):471-81. PubMed ID: 24852802
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G, PRODIGY Investigators.
    JACC Cardiovasc Interv; 2014 Jan 01; 7(1):20-8. PubMed ID: 24332420
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A, Sardi G, Hauville C, Barbash IM, Pakala R, Torguson R, Xue Z, Satler LF, Pichard AD, Waksman R.
    Catheter Cardiovasc Interv; 2013 Apr 01; 81(5):759-65. PubMed ID: 22488756
    [Abstract] [Full Text] [Related]

  • 8. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ, Leon MB, Ball MW, Bajwa HS, Sketch MH, Coleman PS, Stoler RC, Papadakos S, Cutlip DE, Mauri L, Kandzari DE, ENDEAVOR IV Investigators.
    JACC Cardiovasc Interv; 2013 Apr 01; 6(4):325-33. PubMed ID: 23523453
    [Abstract] [Full Text] [Related]

  • 9. Long-term comparative effectiveness of Endeavor zotarolimus-eluting and everolimus-eluting stents in New York.
    Qian F, Zhong Y, Hannan EL.
    Int J Cardiol; 2017 Aug 15; 241():437-443. PubMed ID: 28389121
    [Abstract] [Full Text] [Related]

  • 10. Comparison of 2-year clinical outcomes between zotarolimus-, sirolimus-, and paclitaxel-eluting stents in real life clinical practice.
    Kim JH, Park KW, Lim WH, Shin DH, Chae IH, Choi DJ, Kim HS.
    Catheter Cardiovasc Interv; 2014 Feb 15; 83(3):349-59. PubMed ID: 24654284
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of 5-year outcomes of paclitaxel-eluting and endeavor zotarolimus-eluting stents in New York.
    Qian F, Zhong Y, Hannan EL.
    Catheter Cardiovasc Interv; 2018 Jan 01; 91(1):9-16. PubMed ID: 28303630
    [Abstract] [Full Text] [Related]

  • 14. Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.
    Vardi M, Burke DA, Bangalore S, Pencina MJ, Mauri L, Kandzari DE, Leon MB, Cutlip DE.
    Catheter Cardiovasc Interv; 2013 Dec 01; 82(7):1031-8. PubMed ID: 23737390
    [Abstract] [Full Text] [Related]

  • 15. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B, Yang Y, Yuan Z, Du Z, Wong SC, Généreux P, Lu S, RESOLUTE China RCT Investigators.
    JACC Cardiovasc Interv; 2013 Jul 01; 6(7):664-70. PubMed ID: 23523240
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
    van der Heijden LC, Kok MM, Lam MK, Danse PW, Schramm AR, Jessurun GA, Tjon Joe Gin RM, van Houwelingen KG, Hautvast RW, Linssen GC, Sen H, Löwik MM, IJzerman MJ, Doggen CJ, von Birgelen C.
    Clin Res Cardiol; 2016 Mar 01; 105(3):206-15. PubMed ID: 26329584
    [Abstract] [Full Text] [Related]

  • 18. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
    Sen H, Lam MK, Löwik MM, Danse PW, Jessurun GA, van Houwelingen KG, Anthonio RL, Tjon Joe Gin RM, Hautvast RW, Louwerenburg JH, de Man FH, Stoel MG, van der Heijden LC, Linssen GC, IJzerman MJ, Tandjung K, Doggen CJ, von Birgelen C.
    JACC Cardiovasc Interv; 2015 Jun 01; 8(7):889-99. PubMed ID: 26003019
    [Abstract] [Full Text] [Related]

  • 19. Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: a propensity score-matched analysis.
    Chen KY, Rha SW, Wang L, Li YJ, Li GP, Poddar KL, Park JY, Choi CU, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim CJ, Yoon JH, Chung WS, Seung KB, Park SJ, KAMIR Investigators.
    JACC Cardiovasc Interv; 2012 Sep 01; 5(9):936-45. PubMed ID: 22995881
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.